UPDATE : Wednesday, January 22, 2020
HOME Pharma
SCM Life Science, MitoImmune Therapeutics to develop new treatment
  • By Lee Han-soo
  • Published 2019.07.11 16:40
  • Updated 2019.07.11 16:57
  • comments 0

SCM Life Science said that it has agreed with MitoImmune Therapeutics to develop a new treatment, which combines clonal mesenchymal stem cells (cMSC) and mitochondria technology.

SCM Life Science CEO Rhee Byung-gun (left) and MitoImmune Therapeutics CEO Kim Soon-ha signed a business partnership contract at the former's headquarters in Incheon, on Thursday.

The two companies will carry out the agreement soon to start research into therapeutic agents for intractable, inflammatory, and rare diseases.

"We hope to develop a drug for rare intractable diseases that can enter the global market by combing MitoImmune Therapeutics' mitochondrial control technology and our cMSC technology," SCM Life Science CEO Rhee Byung-gun said.

MitoImmune Therapeutics CEO Kim Soon-ha also said, "Our company expects that its mitochondria platform will provide a differentiated solution for the treatment of rare intractable diseases by modulating mitochondrial functions for SCM Life Science's cMSC."


<© Korea Biomedical Review, All rights reserved.>

Other articles by Lee Han-soo
iconMost viewed
Comments 0
Please leave the first comment.
Back to Top